{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-024480","form_type":"8-K","ticker":"TGTX","cik":"0001001316","company_name":"TG THERAPEUTICS, INC.","filed_at":"2025-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.103291+00:00","generated_at":"2026-05-17T21:18:17.202140+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"TG Therapeutics Q2 BRIUMVI revenue $138.8M (+91% YoY); raises FY guidance to $570-575M","bullets":["Q2 2025 total revenue $141.1M; BRIUMVI U.S. net sales $138.8M, up 91% YoY vs $72.6M.","Net income $28.2M in Q2 2025 vs $6.9M in Q2 2024; cash and securities $278.9M.","Raises FY 2025 BRIUMVI U.S. net revenue guidance to $570-575M (prior $560M); total global revenue target ~$585M.","R&D expense $31.8M (up from $17.6M) driven by subcutaneous development; SG&A $55.6M (up from $38.8M) for commercialization.","Pipeline: Phase 3 ENHANCE trial for consolidated IV dosing ongoing; Phase 1 azer-cel in autoimmune diseases first patient dosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-024480","json":"https://secwatch.observer/filing/0001437749-25-024480.json","markdown":"https://secwatch.observer/filing/0001437749-25-024480.md","text":"https://secwatch.observer/filing/0001437749-25-024480.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001316/000143774925024480/0001437749-25-024480-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001316/000143774925024480/tgtx20250724_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:18:17.202140+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}